SFDA approves registration of Pemazyre for cholangiocarcinoma

November 11, 2025

Saudi Gazette reportRIYADH — The Saudi Meals and Drug Authority (SFDA) has authorized the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with regionally superior or metastatic cholangiocarcinoma.

Supply hyperlink

Is Casemiro leaving Manchester United? The Purple Devils linked to former Actual Madrid market goal

Saudi Arabia, Kuwait signal 4 MoUs for bolstering bilateral ties

Popular

SFDA approves registration of Pemazyre for cholangiocarcinoma

Subscribe

Crown Prince, El-Sisi focus on Mideast developments

Pakistani conjoined twins arrive in Riyadh for separation evaluation

Crown Prince, Egypt’s president meet over iftar in Jeddah

HADAF: SR2.6 billion value of accredited alternatives for SMEs by means of “Fursa” platform in 2025

Mohammed Abdu to reduce concert events, prioritize nationwide events

More like this
Related

Crown Prince, El-Sisi focus on Mideast developments

Pakistani conjoined twins arrive in Riyadh for separation evaluation

Crown Prince, Egypt’s president meet over iftar in Jeddah

HADAF: SR2.6 billion value of accredited alternatives for SMEs by means of “Fursa” platform in 2025

About us

The latest

Crown Prince, El-Sisi focus on Mideast developments

Pakistani conjoined twins arrive in Riyadh for separation evaluation

Crown Prince, Egypt’s president meet over iftar in Jeddah

Subscribe

SFDA approves registration of Pemazyre for cholangiocarcinoma

Subscribe

More like thisRelated

About us

The latest

Subscribe

More like this
Related